---
title: "Euda Health signs MOU with GO POSB Organoids, Shenzhen Inno on iPSC-derived oncology cell therapies"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294110361.md"
description: "Euda Health signed a tri-party MOU with GO POSB Organoids and Shenzhen Innovation Immunotechnology to collaborate on iPSC-derived oncology cell therapies. The partnership targets the development, manufacturing, and commercialization of off-the-shelf therapies, including iPSC-based NK-TCR programs. This collaboration supports Euda’s strategy to expand its distribution of science-backed wellness and non-invasive healthcare offerings across Asia."
datetime: "2026-07-28T20:32:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294110361.md)
  - [en](https://longbridge.com/en/news/294110361.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294110361.md)
generator: "portal-rs"
---

# Euda Health signs MOU with GO POSB Organoids, Shenzhen Inno on iPSC-derived oncology cell therapies

-   Euda Health signed a tri-party MOU with GO POSB Organoids, Shenzhen Innovation Immunotechnology to collaborate on iPSC-derived cell therapies. \* Parties target development, manufacturing, commercialization of off-the-shelf oncology cell therapies, including iPSC-based NK-TCR programs. \* Collaboration supports Euda’s strategy to expand distribution of science-backed wellness, non-invasive healthcare offerings across Asia. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Euda Health Holdings Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-035013), on July 28, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [EUDA.US](https://longbridge.com/en/quote/EUDA.US.md)
- [EUDAW.US](https://longbridge.com/en/quote/EUDAW.US.md)

## Related News & Research

- [EUDA Health signs MOU with GO POSB, SIIT to develop off-the-shelf iPSC cell therapies](https://longbridge.com/en/news/294340008.md)
- [OS Therapies Announces Prospectus for Secondary Share Resales](https://longbridge.com/en/news/298655658.md)
- [OS Therapies shareholders approve amended 2023 incentive compensation plan at annual meeting](https://longbridge.com/en/news/298500152.md)
- [OS Therapies files prospectus for resale of up to 5,874,094 shares by selling stockholders](https://longbridge.com/en/news/298647480.md)
- [ARTV: Pivotal phase III trial in refractory RA advances, aiming for first-in-class deep B-cell depletion](https://longbridge.com/en/news/298481605.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**